There are currently 387 clinical trials in Grand Rapids, Michigan looking for participants to engage in research studies. Trials are conducted at various facilities, including Spectrum Health - Butterworth Campus, Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Trinity Health Grand Rapids Hospital and CCOP - Grand Rapids. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NCT05095376
Recruiting
This phase III trial compares the effect of adding lomustine to standard chemotherapy with temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. MGMT methylated tumors are more likely to respond to temozolomide chemotherapy. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Lomusti... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/04/2025
Locations: Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids, Michigan +2 locations
Conditions: Glioblastoma, Gliosarcoma
Register for Updates
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NCT05946213
Recruiting
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period of time. This trial is evaluating if shorter duration radiation preve... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids, Michigan
Conditions: Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Prostate Adenocarcinoma
Register for Updates
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
NCT02235857
Recruiting
Liposorber® LA-15 System is a blood purification therapy that selectively removes malignant lipoproteins including low density lipoprotein from circulating blood flow and rapidly reduces the plasma cholesterol level. The system was originally developed for the treatment of patients with serious dyslipidemia such as familial hypercholesterolemia and then applied to improve the dyslipidemia, a common complication of nephrotic syndrome and found to bring about improvement not only with the dyslipid... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
03/03/2025
Locations: Helen DeVos Children's Hospital, Grand Rapids, Michigan
Conditions: Focal Segmental Glomerulosclerosis
Register for Updates
Rinatabart Sesutecan (Rina-S) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT05579366
Recruiting
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: START Midwest, Grand Rapids, Michigan
Conditions: Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Mesothelioma, Triple Negative Breast Cancer, High Grade Epithelial Ovarian Cancer, Breast Adenocarcinoma, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-Resistant Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC), High Grade Serous Ovarian Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)
Register for Updates
Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)
NCT06151197
Recruiting
This study will assess the efficacy, safety, and tolerability of EN3835 compared to placebo in the treatment of PFI (also known as Ledderhose disease).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Endo Site 16, Grand Rapids, Michigan
Conditions: Plantar Fibromatosis, Ledderhose Disease
Register for Updates
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
NCT05614063
Recruiting
The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Cornwell Health, Grand Rapids, Michigan
Conditions: Focal Onset Seizures
Register for Updates
Study of RET Inhibitor TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities
NCT04683250
Recruiting
Phase 1 and 2 trial to study the safety, pharmacokinetics, and efficacy of TAS0953/HM06 in patients with advanced solid tumors with RET gene abnormalities. Phase 1 aims to determine the Maximum Tolerated Dose (MTD) and identify the Recommended Phase 2 Dose (RP2D) to be used in phase 2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: START Midwest - Cancer & Hematology Centers of Western Michigan, Grand Rapids, Michigan
Conditions: RET-altered Non Small Cell Lung Cancer, RET-altered Solid Tumors
Register for Updates
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
NCT05667142
Recruiting
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS).
Gender:
ALL
Ages:
12 years and above
Trial Updated:
02/28/2025
Locations: Spectrum Health, Grand Rapids, Michigan
Conditions: Primary Generalized Tonic-Clonic Seizures
Register for Updates
TTVR Early Feasibility Study
NCT04433065
Recruiting
The objective of this early feasibility study is to gain early clinical insight into the performance of the Intrepid transcatheter tricuspid valve replacement (TTVR) system intended for transfemoral access to deliver a self-expanding bioprosthetic valve within the tricuspid valve.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Corewell Health, Grand Rapids, Michigan
Conditions: Tricuspid Regurgitation
Register for Updates
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738
Recruiting
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Research Site, Grand Rapids, Michigan
Conditions: Non-small Cell Lung Cancer
Register for Updates
A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
NCT05768269
Recruiting
This study is designed to collect long-term safety and survival data from participants previously treated in an eligible Century-sponsored index trial. This is an observational study, and the elements of the study design allow for important follow-up for safety, survival, and the continued evaluation of any late adverse events (AEs) that may appear after treatment with such cellular products. Additionally, collection of persistence data from participants will support the identification of any lo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Corewell Health, Grand Rapids, Michigan
Conditions: Hematological Malignancy, Solid Tumor Malignancy
Register for Updates
QTX3544 in Patients with Advanced Solid Tumors with KRAS G12V Mutations
NCT06715124
Recruiting
Phase 1 study to determine the safety, tolerability, and anti-tumor activity of QTX3544 as a single agent or in combination with cetuximab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: South Texas Accelerated Research Therapeutics, LLC Midwest, Grand Rapids, Michigan
Conditions: Advanced Solid Tumors
Register for Updates